Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 22, 2007
app pub date -
May 16, 2006
filing date -
May 16, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention provides combinations of pharmaceutically active agents (i.e. statins and negatively charged phospholipids) for treating or preventing atherosclerosis or coronary artery disease (CAD) in mammals, and methods therefore. In particular, these combinations and methods find utility for achieving one or more of the following effects in a subject: (1) a reduction in plasma levels of low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) cholesterol; (2) an increase in plasma levels of high-density lipoprotein (HDL) cholesterol; and (3) a reduction in plasma levels of triglycerides.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully